Features of multi-organ involvement and management strategies in AIDS-related Kaposi sarcoma

doi:10.16138/j.1673-6087.2026.01.10

Abstract

Abstract:

Kaposi sarcoma (KS) is a multicentric tumor closely associated with immunosuppression and KS-associated herpesvirus (KSHV) infection. The synergistic interaction between KSHV infection and human immunodeficiency virus (HIV) infection promotes the occurrence and progression of acquired immunodeficiency syndrome (AIDS)-associated KS (AIDS-KS). AIDS-KS is one of the most common malignancies in AIDS patients and thus requires high clinical attention. This article systematically reviews the multicentric pathogenesis of AIDS-KS, the specific clinical manifestations of involvement in different organs and stratified diagnostic and therapeutic strategies, with particular emphasis on the importance of combining antiretroviral therapy (ART) and targeted therapy in disease management. The implementation of individualized and multidisciplinary comprehensive management strategies can better control disease progression and improve patients’ quality of life as well as prognosis.

Key words: acquired immunodeficiency syndrome, Kaposi sarcoma, pathogenesis, organ involvement, antiretroviral therapy, diagnostic and therapeutic strategies

CLC Number:

ZHANG Yaping, WANG Li, HE Yuanhong, YIN Ke, YANG Tongtong. Features of multi-organ involvement and management strategies in AIDS-related Kaposi sarcoma[J]. Journal of Internal Medicine Concepts & Practice, 2026, 21(01): 68-73.

References 27

[1]	吕亮, 张英. 艾滋病型卡波西肉瘤的临床研究进展[J]. 中国中西医结合皮肤性病学杂志, 2021, 20(6):645-647.
	Lv L, Zhang Y. Advances in clinical research on AIDS-related Kaposi sarcoma[J]. Chin J Dermato Venerol Integ Trad W Med, 2021, 20(6):645-647.
[2]	Arbune M, Padurariu-Covit MD, Rebegea LF, et al. AIDS related Kaposi’s sarcoma: a 20-year experience in a clinic from the south-east of Romania[J]. J Clin Med, 2021, 10(22):5346. doi: 10.3390/jcm10225346
[3]	朱晋峰, Kumar Saurabha, Nancy Kablay, 等. 艾滋病相关卡波西肉瘤104例临床表现、治疗及疗效分析[J]. 现代肿瘤医学, 2014, 22(9):2199-2203.
	Zhu JF, Saurabha K, Kablay N, et al. Clinical manifestation, therapy and efficacy analysis of 104 cases of AIDS -associated Kaposi’s sarcoma[J]. Modern Oncology, 2014, 22(9):2199-2203.
[4]	Dalla Pria A, Pinato DJ, Bracchi M, et al. Recent advances in HIV-associated Kaposi sarcoma[J]. F1000Res, 2019, 8:F1000 Faculty Rev-970.
[5]	Abe S, Nakamoto T, Aoki T, et al. HIV-associated multicentric Castleman disease with Kaposi sarcoma: A case report with 120-week follow-up of HHV-8 after remission[J]. J Infect Chemother, 2025, 31(10):102806. doi: 10.1016/j.jiac.2025.102806
[6]	Liew YCC, Tam YCS, Oh CC. Treatments for AIDS/HIV-related Kaposi sarcoma: a systematic review of the literature[J]. Int J Dermatol, 2022, 61(11):1311-1324. doi: 10.1111/ijd.16318
[7]	Gonçalves PH, Uldrick TS, Yarchoan R. HIV-associated Kaposi sarcoma and related diseases[J]. AIDS, 2017, 31(14):1903-1916. doi: 10.1097/QAD.0000000000001567
[8]	Mamimandjiami AI, Engone-Ondo JD, Moussavou-Boundzanga P, et al. Kaposi’s sarcoma: a non-communicable outcome mainly prompted by communicable diseases in sub-Saharan Africa[J]. Int J Mol Sci, 2025, 26(20):10198. doi: 10.3390/ijms262010198
[9]	Lage SL, Ramaswami R, Rocco JM, et al. Inflammasome activation in patients with Kaposi sarcoma herpesvirus-associated diseases[J]. Blood, 2024, 144(14):1496-1507. doi: 10.1182/blood.2024024144
[10]	Tang ASO, Teh YC, Chea CY, et al. Disseminated AIDS-related Kaposi’s sarcoma[J]. Oxf Med Case Reports, 2018, 2018(12):omy107. doi: 10.1093/omcr/omy107
[11]	Yarchoan R, Uldrick TS. HIV-Associated Cancers and Related Diseases[J]. N Engl J Med, 2018, 378(11):1029-1041. doi: 10.1056/NEJMra1615896
[12]	Cesarman E, Damania B, Krown SE, et al. Kaposi sarcoma[J]. Nat Rev Dis Primers, 2019, 5(1):9. doi: 10.1038/s41572-019-0060-9
[13]	Wan Q, Tucker AJ, Zhao J. Oncogenic Mechanisms of Kaposi’s sarcoma-associated herpesvirus on cell metabolism and cell transformation[J]. J Med Virol, 2025, 97(8):e70565
[14]	张予, 李婷婷, 康晓静, 等. 卡波西肉瘤免疫相关机制及免疫治疗研究进展[J]. 临床皮肤科杂志, 2024, 53(3):189-192. doi: 10.16761/j.cnki.1000-4963.2024.03.016
	Zhang Y, Li TT, Kang XJ, et al. Research progress on immune related mechanism and immunotherapy of Kaposi’s sarcoma[J]. J Clin Dermatol, 2024, 53(3):189-192. doi: 10.16761/j.cnki.1000-4963.2024.03.016
[15]	Byun M, Abhyankar A, Lelarge V, et al. Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma[J]. J Exp Med, 2010, 207(11):2307-2312. doi: 10.1084/jem.20101597
[16]	Requena C, Alsina M, Morgado-Carrasco D, et al. Kaposi sarcoma and cutaneous angiosarcoma: guidelines for diagnosis and treatment[J]. Actas Dermosifiliogr (Engl Ed), 2018, 109(10):878-887.
[17]	中国医师协会皮肤科医师分会, 中国研究型医院学会皮肤科学专业委员会. 中国卡波西肉瘤诊疗专家共识（2023版）[J]. 中华皮肤科杂志, 2023, 56(10):899-906. doi: 10.35541/cjd.20230261
	China Dermatologist Association, Dermatology Professional Committee of Chinese Research Hospital Society. Consensus on the diagnosis and treatment of Kaposi’s sarcoma in China (2023)[J]. Chin J Dermatol, 2023, 56(10):899-906. doi: 10.35541/cjd.20230261
[18]	黄华, 施裕新, 谢汝明, 等. 艾滋病合并肺部卡波西肉瘤的 CT 表现[J]. 放射学实践, 2015, 30(9):905-908.
	Huang H, Shi YX, Xie RM, et al. The CT findings of pulmonary Kaposi sarcoma in AIDS patients[J]. Radiol Practice, 2015, 30(9):905-908.
[19]	Ma S, Chen X, Lai Y. Global research landscape of HIV and Kaposi’s sarcoma: a visualized bibliometric analysis[J]. Front Microbiol, 2025, 16:1601245. doi: 10.3389/fmicb.2025.1601245
[20]	Ramaswami R, Kask AS, D’Amico L, et al. Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma[J]. J Immunother Cancer, 2025, 13(2):e010291. doi: 10.1136/jitc-2024-010291
[21]	Zeng Y, Prasad R, King RD, et al. AIDS-related Kaposi sarcoma associated with steroid-unresponsive periorbital lymphedema that responded to chemotherapy[J]. Am J Case Rep, 2023, 24:e938801. doi: 10.12659/ajcr.938801
[22]	Gambichler T, Susok L. PD-1 blockade for disseminated Kaposi sarcoma in a patient with atopic dermatitis and chronic CD8 lymphopenia[J]. Immunotherapy, 2020, 12(7):451-457. doi: 10.2217/imt-2019-0183
[23]	Polizzotto MN, Uldrick TS, Wyvill KM, et al. Pomalidomide for symptomatic Kaposi’s sarcoma in people with and without HIV infection: a phase Ⅰ/Ⅱ study[J]. J Clin Oncol, 2016, 34(34):4125-4131. doi: 10.1200/JCO.2016.69.3812
[24]	Uldrick TS, Wyvill KM, Kumar P, et al. Phase Ⅱ study of bevacizumab in patients with HIV-associated Kaposi’s sarcoma receiving antiretroviral therapy[J]. J Clin Oncol, 2012, 30(13):1476-1483. doi: 10.1200/JCO.2011.39.6853
[25]	Uldrick TS, Gonçalves PH, Abdul-Hay M, et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-a phase 1 study[J]. JAMA Oncol, 2019, 5(9):1332-1339. doi: 10.1001/jamaoncol.2019.2244
[26]	Delyon J, Biard L, Renaud M, et al. PD-1 blockade with pembrolizumab in classic or endemic Kaposi’s sarcoma: a multicentre, single-arm, phase 2 study[J]. Lancet Oncol, 2022, 23(4):491-500. doi: 10.1016/S1470-2045(22)00097-3
[27]	Ramaswami R, Lurain K, Yarchoan R. Oncologic treatment of HIV-associated Kaposi sarcoma 40 years on[J]. J Clin Oncol, 2022, 40(3):294-306. doi: 10.1200/JCO.21.02040